This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vision-Sciences Announces Revenue Of $4.5 Million For Third Quarter And $12.1 Million For First Nine Months Of Fiscal 2014

ORANGEBURG, N.Y., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath ® technology, today announced financial results for the third quarter and first nine months of fiscal year 2014, ended December 31, 2013.

Third Quarter Fiscal Year 2014 Highlights
  • Net sales increased by 14% to $4.5 million compared with $4.0 million in the third quarter of fiscal 2013;
  • On a sequential basis, net sales increased by 14% compared with $4.0 million in the second quarter of fiscal 2014;
  • Operating loss improved by 3% to $1.5 million compared to the same quarter last fiscal year;
  • Net loss improved by 1% to $1.6 million, or ($0.03) per basic and diluted share, compared to the same quarter last fiscal year;
  • Positive outcomes of a clinical study that evaluated the durability and microbial barrier properties of EndoSheath ® technology in the flexible cystoscopy setting were published in the peer-reviewed journal BMC Urology;
  • Launched an authorized fiber and video endoscope repair center for Europe; and
  • Selected as preferred vendor for endoscopy equipment by 21st Century Oncology.

First Nine Months of Fiscal Year 2014 Highlights
  • Net sales increased by 9% to $12.1 million compared with $11.1 million in the first nine months of fiscal 2013;
  • Operating loss improved by 20% to $5.2 million compared to $6.5 million in the same period last fiscal year; and
  • Net loss improved by 37% to $5.3 million, or ($0.12) per basic and diluted share, compared to $8.5 million, or ($0.18) per basic and diluted share, in the same period last fiscal year.

"I am pleased with the revenue growth we achieved this quarter on both a year-over-year and sequential basis," commented Howard Zauberman, President and Chief Executive Officer of Vision-Sciences, Inc. "Our relationship with Stryker remains strong and we are pleased with their growth in ureteroscope placements, which continues to be a key driver of our revenues. We expect revenue growth in coming quarters will be consistent with the last nine months as we complete our turnaround, and seek to reduce our operating loss on a go-forward basis."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs